Delta-Fly Pharma, Inc. (TSE: 4598)
Health Care · Biotechnology · JP
¥109.00
+2.83% today · -82.2% 1Y
Delta-Fly Pharma, Inc. (TSE: 4598) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.81M and employs 12 people.
Over the last twelve months the share price has lost 82.2%, trading between 92.00 and 700.00.
Tweenvest scores Delta-Fly Pharma, Inc. across four factors: quality 24/100. Its strongest factor is quality.
4598 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.81M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -134.57
- Dividend yield
- —
- Beta (5Y)
- -0.71
- 52-week high
- ¥700.00
- 52-week low
- ¥92.00
- Avg volume (3M)
- —
- Shares outstanding
- 14.30M
- Employees
- 12
- Next earnings
- —
About Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
- ISIN
- JP3549370009
- Founded
- 2010
- Listed since
- Oct 12, 2018
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.01 | +0.56% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.66 | +0.18% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.81 | +0.73% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.67 | +0.93% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.34 | +0.82% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $155.30 | +11.82% |
Figures last refreshed Aug 18, 2026.